Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NYSE:QGEN

Qiagen Q1 2026 Earnings Results & Report

Qiagen logo
$46.20 +0.04 (+0.08%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Qiagen met analyst earnings expectations and missed on revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of $0.54 versus the $0.54 consensus estimate, while revenue of $492.32 million fell short of the $496.15 million estimate by $3.83 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Qiagen EPS Results

Actual EPS
$0.54
Consensus EPS
$0.54
Beat/Miss
Met Expectations
One Year Ago EPS
$0.56
EPS Beat Rate
6 of last 8 quarters

Qiagen Revenue Results

Actual Revenue
$492.32 million
Expected Revenue
$496.15 million
Beat/Miss
Missed by -$3.83 million
YoY Revenue Growth
N/A

Upcoming Earnings

Qiagen's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Qiagen Q1 2026 Earnings FAQ

Qiagen (NYSE:QGEN) reported earnings of $0.54 per share for Q1 2026, matching the consensus estimate of $0.54. The report was announced on Thursday, May 7, 2026.

Qiagen reported revenue of $492.32 million for Q1 2026, against a consensus estimate of $496.15 million.

Qiagen's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Qiagen on the company's earnings history page.

Qiagen Earnings Headlines

Qiagen (NYSE:QGEN) Stock Gets Price Target Bump from JPMorgan Chase & Co.
October 16 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31123889
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
October 13 at 4:05 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261013545546/en/qiagen-convenes-global-tuberculosis-experts-as-new-pressures-challenge-progress-against-tuberculosis/
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 16 at 1:00 AM  |  Weiss Ratings (Ad)
Reviewing Standard BioTools (NASDAQ:LAB) & Qiagen (NYSE:QGEN)
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107780
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
October 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261006274304/en/qiagen-expands-ai-powered-bioinformatics-for-research-and-drug-discovery/
Qiagen gains on report talks with strategic buyer have advanced
October 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4649918-qiagen-gains-on-report-talks-with-strategic-buyer-have-advanced
See More Qiagen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qiagen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qiagen and other key companies, straight to your email.

About Qiagen

Qiagen (NYSE:QGEN) (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data. Its products support applications in academic and pharmaceutical research, biotechnology, forensic testing, veterinary medicine and clinical healthcare.

QIAGEN was founded in 1984 and has expanded from a supplier of molecular biology research tools into a global life sciences and diagnostics company. Headquartered in Venlo, the Netherlands, it serves customers through operations and distribution networks across North America, Europe, Asia and other international markets. The company is led by Chief Executive Officer Thierry Bernard.

View Qiagen Profile
Earnings Tools